Home
  • Health & Wellness
  • Conditions
  • Insurance & Money

Company Seeks To Increase Minority Representation In Clinical Drug Trials

Home » General Health Articles » Drug Clinical Trials

All About:
  • Drug Clinical Trials

Submitted by hareyan on Nov 9th, 2007
Posted under:
  • Drug Clinical Trials

Ensuring that clinical research studies include a diverse population ofparticipants is "important because type 2 diabetes and a host of otherdiseases affect ethnic minority groups differently," the Indianapolis Star reports.

According to the Star, FDAhas been urging pharmaceutical companies to more closely examine howtheir drugs work in minority populations. An agency study showed thatfrom 1995 to 1999 minorities were seriously underrepresented in 2,581registered clinical trials for 185 drugs. Minorities often representfewer than 15% of patients in clinical drug trials.

Withoutinformation on how the drugs affect minorities, products can reach themarket based on flawed data, Nancy Jewell, president and CEO of the Indiana Minority Health Coalition,said. "It's a major issue in the minority community. If you don't havea minority partner in a clinical trial, there might be a possibilitythat a drug might not be as effective (for a) certain race or ethnicgroup," Jewell added.

Indianapolis-based company Anaclim, founded by two Eli Lillyexecutives in 2005, helps companies recruit minority participants fordrug trials, as well as minority physicians to run the tests.Currently, Anaclim is working on nine clinical trials that are studyingdiabetes and cardiovascular disease. It also has worked for smallbiotechnology companies, Rex Alexander, Anaclim's vice president ofclinical operations and co-founder, said.

Alfonso Alanis, CEOand co-founder of the company, said, "Minority investigators have beenignored in the clinical research business," adding, "They're going tobe major consumers of resources. It makes no sense to develop a drug ina population of patients that's not going to use the drug." Alexanderand Alanis plan to expand their company to areas outside the U.S., suchas Central America, Europe and India, in an effort to "open doors toeven more diverse populations," according to the Star (Bowen, Indianapolis Star, 11/6).
\tReprinted with permission from kaisernetwork\t\t\t\t\t\t\t\t<!--\t\t@page { size: 8.5in 11in; margin: 0.79in }\t\tP { margin-bottom: 0.08in }\t\tA:link { color: #0000ff }\t-->\t

Reprinted with permission fromkaisernetwork.org.You can view the entire KaiserWeekly Health Disparities Report, search the archives,and sign up for email delivery at kaisernetwork.org/email. The Kaiser Weekly Health Disparities Report is published forkaisernetwork.org, a free service of The Henry J. Kaiser FamilyFoundation. 2007 Advisory Board Company and Kaiser FamilyFoundation. All rights reserved.

Source: 
kaisernetwork.org
  • Login or register to post comments
Write For EmaxHealth

Similar Stories

  • More Training In Clinical Trial Design Needed
  • New York State To Allow Payment For Eggs Used In Research
  • Anti-Thyroid Drug Associated with Serious Liver Injury
  • Group Urges FDA To Halt Prasugrel Review
  • Researchers Start New Anti-Cancer Drug Trial

Enter your email address:

 Subscribe in a reader
  • R788 Shows Benefit In Diffuse Large B-Cell And SLL/CLL
  • Amicus Therapeutics Initiates Trial Of AT2220 In Pompe Disease
  • Wyeth To Examine TORISEL Plus Avastin For Kidney Cancer Treatment
  • Maintenance Therapy Is Associated With Improved Renal Function
  • Quest PharmaTech Announces Positive Results From Actinic Keratosis Trial
  • ViroPharma Completes Study Of Maribavir In Stem Cell Transplant Patients
  • Favrille Announces Positive Results From Specifid Trial
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
  • Health RSS Feeds